



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/68, 33/569	A1	(11) International Publication Number: WO 97/37227 (43) International Publication Date: 9 October 1997 (09.10.97)
(21) International Application Number: PCT/NL97/00166 (22) International Filing Date: 2 April 1997 (02.04.97) (30) Priority Data: 96200917.1 3 April 1996 (03.04.96) EP (34) Countries for which the regional or international application was filed: NL et al. (71) Applicant (for all designated States except US): INSTITUUT VOOR DIERHOUDERIJ EN DIERGEZONDHEID (ID-DLO) [NL/NL]; Edelhertweg 15, NL-8219 PH Lelystad (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): SCHREUDER, Bram, Edward, Cornelis [NL/NL]; Rozengaard 13-10, NL-8212 DE Lelystad (NL). VAN KEULEN, Lucius, Johannes, Mattheus [NL/NL]; Vletweide 194, NL-3981 ZR Bunnik (NL). VROMANS, Maria, Elisabeth, Wilhelmina [NL/NL]; Westkaap 8, NL-8244 EE Lelystad (NL). LANGEVELD, Johannes, Pieter, Maria [NL/NL]; Stedenmeen 12, NL-3844 JB Harderwijk (NL). SMITS, Marinus, Adrianus [NL/NL]; Mastmeen 18, NL-3844 KE Harderwijk (NL).		(74) Agent: SMULDERS, Th., A., H., J.; Vereenigde Octrooibureaux, Nicuwc Parklaan 97, NL-2587 BN The Hague (NL). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: METHOD FOR THE DETECTION OF PRION DISEASES (57) Abstract The invention provides methods for the detection of prion diseases, such as scrapie of sheep, bovine spongiform encephalopathy of cattle, Creutzfeld-Jacob disease of man, whereby aberrant proteins or prion proteins are detected in tissues which can be sampled from live animals.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Title: Method for the detection of prion diseases

FIELD OF THE INVENTION

The invention relates to the field of prion diseases, also called spongiform encephalopathies (SEs), such as
5 scrapie of sheep, bovine spongiform encephalopathy (BSE, mad-cow disease) of cattle, Creutzfeld-Jacob disease (CJD) and kuru of man. Prion diseases are transmissible via among others ingestion of or inoculation with prion
10 proteins, can occur iatrogenically, but can also happen occasionally or on a hereditary basis without evidence of transmission.

INTRODUCTION

15 Prion diseases are a focal point of public interest, recently fuelled by the detection of unexpected cases of CJD in teenagers and in farmers, both in Great Britain, where transmisson of prion proteins from cattle to humans via meat consumption is postulated, thus indicating the
20 transmission of BSE to humans, thereby causing CJD.

Several factors enhance public concern:

- a) the nature of the causative agent, the so called prion protein, of SEs is unknown or at least controversial,
 - b) whatever its nature, the agent is highly resistant to
25 procedures that eliminate other infectious agents (e.g. heating);
 - c) therapeutical interventions are apparently not possible, once symptoms occur;
 - d) SEs have an extremely long incubation period;
 - 30 e) practical, sensitive and specific diagnostic methods to be used during the preclinical phase are not available.
- This all adds to the general feeling of "living with a time-bomb". Not only the possible presence of prion

proteins in meat and meat products poses a health threat, also the possible presence of prion proteins in blood and blood products used in transfusion, the presence in pharmaceutical products of animal origin, in cosmetics of animal origin, in sera used for cell culture, in short, in an extensive array of products of animal origin, pose possible threats to human and animal health.

Until now, confirmatory diagnosis of scrapie and also other transmissible spongiform encephalopathies depended on histological examination of the brain, collected during post-mortem examination from animals or humans with clinical signs of the disease. Deposits of an aberrant or altered protein (PrP^{Sc}, prion protein) can be detected in the brain of diseased animals. This protein is very insensitive to methods, such as proteinase K digestion, that otherwise denature, lyse or remove normal proteins. The aberrant protein is considered central in the pathogenesis of prion disease. Albeit not infectious in a classical microbiological way due to the absence of specific nucleic acid, the aberrant protein itself is seen as the causal agent, and when a susceptible animal obtains such an aberrant protein in its body (i.e. by ingestion, inoculation or via mutation of the gene of the normal version of the PrP protein, PrP^C) a chain reaction may start that ultimately will lead to a clinical manifestation of prion disease. The chain reaction entails the formation of more aberrant proteins formed out of the normal protein present in the animal's body. Normal and aberrant forms will interact in such a way that more aberrant forms are produced. Since the aberrant form is very resistant to proteolysis, deposits of the converted prion protein will be formed, especially in the brain and other parts of the central nervous system (CNS), giving rise to the spongiform encephalopathy and thus clinical manifestations of brain disease.

As SE-infected or affected animals and man lack a disease-specific immune response, identifying individuals before they develop clinical signs (which can take years) has been practically impossible so far. No biochemical, haematological, or gross pathological abnormalities are consistently associated with SEs. The diagnosis of SEs, therefore, depends on the recognition of clinical signs, electro-encephalography or magnetic resonance imaging techniques (both used only in human patients), or the more invasive method of taking brain-biopsies. The final diagnosis is made during autopsy, by histological examination of the brain. The neuro-pathological lesions, consisting of vacuolation (spongiform change) of the grey matter associated with gliosis and neuronal loss, are generally sufficiently characteristic. Further confirmation is possible by demonstrating scrapie associated fibrils (SAFs) in brain extracts, or by demonstrating the presence of its constituent protein, PrP^{Sc}. PrP^{Sc} is associated with the disease and is an aberrant form of the host encoded prion protein (PrP), the aberrant form is induced by a conformational change. PrP^{Sc} can be detected by immunological techniques such as Western blotting or immunohistochemistry. The latter technique is gradually becoming more and more accepted as a reliable diagnostic tool for clinical cases, in both the human and veterinary SE field.

The search for a practical preclinical diagnostic test has been and continues to be a main topic of research. This generally focuses on the detection of infectivity using a bio-assay, or the detection of the disease associated PrP^{Sc}. The bio-assay, in spite of being the most sensitive detection method, is far too cumbersome and time-consuming to ever become a practical diagnostic method: test results might become available long after the patient has passed away.

Most researchers have therefore focused on techniques to detect PrP^{Sc}. Although not all researchers agree with

the statement that PrP^{Sc} is the causative agent, most, if not all, agree that the association of the presence of PrP^{Sc} and disease has been firmly established. Detection of PrP^{Sc} in tissues outside the CNS would allow sampling through less invasive methods than brain biopsies, thereby brightening prospects for a practical preclinical diagnostic technique substantially. Various tissues have been used in an attempt to develop an early detection technique: blood, urine, tissue fibroblasts, and, particularly in the animal field, lymphoid tissue. A short summary of the most promising and striking ones is given here (for an extensive review see Schreuder, 1994a, 1994b).

Blood: In human SEs, there is the often disputed experimental transmission of CJD from buffy coat samples of human CJD-patients to rodents (Muaramoto et al., 1993), but there is little or no indication that blood and specifically, buffy coat contains any infectivity in animals affected naturally with scrapie, either in clinical or in preclinical stages (Fraser and Dickinson, 1978; Hadlow et al., 1982). Interesting results have recently been reported by Meiner et al. (1992) who detected PrP^{Sc} in peripheral tissues, both in cultured fibroblasts and in monocytes, in a group of eight CJD patients carrying the codon 200 mutation and suffering from clinical disease. These authors used both Western blotting and immunocytochemistry techniques. Their publication, however, appears to have had no follow-up and even if these results could be confirmed, the chances for a reliable blood test seem remote, at least in the case of animal SEs and given the number of negative reports from literature (reviewed in Brown, 1995).

Urine: Only once has a claim been made that infectivity in urine was demonstrated in a case of CJD, by transmitting it to mice. The same author was, however, unable to repeat this experiment (Brown, 1995). A totally different approach was reported recently (Brugere et al.,

1991). Urine from scrapie affected and control animals was tested in a voltametric method by repeated capillary micro-electrolysis, which allowed discrimination of these two groups. This approach appeared promising, but, its value in detecting preclinical stages of in particular BSE could not be confirmed.

Lymphoid tissue: Lymphoid tissue has apparently not been used in the field of diagnosing human SEs, it has, however, in the veterinary field. The already classical work by Hadlow has shown that in the lymphoid tissue of naturally infected scrapie sheep, infectivity was detectable by bio-assay as early as 10-14 months of age. This was before any infectivity in the CNS was found (Hadlow et al., 1980). Western blotting has revealed the presence of PrP^{Sc} in the spleen of scrapie-infected mice (Diringer et al., 1983; Doi et al., 1988), in some cases PrP^{Sc} was detected as early as 4 weeks after experimental infection. Pooled lymph nodes from these mice also contained PrP^{Sc}. Similarly, also using Western blotting, PrP^{Sc} was detected fairly consistently in a group of naturally infected sheep showing clinical signs of scrapie, in samples from the CNS, spleen, and lymph nodes (Ikegami et al, 1991). The value of this Western blotting technique was, at least for clinical cases, confirmed by other groups. The results, however, from a group of experimentally infected sheep that were killed at 16, 18 and 21 months after inoculation but before clinical signs developed, were inconsistent and difficult to evaluate: PrP^{Sc} was detected in spleen samples of only 3 out of 12 supposedly positive animals, with lymph node samples only weak or doubtful results, but no positive results were found, illustrating the insensitivity of this technique. Therefore, using Western blotting techniques in pre-clinical diagnoses of TSE give erratic and not reliable results.

The reason for these erratic results can be found in the method to prepare the PRP^{Sc} protein (present in the

affected tissues) and dissociate or separate it from the normal cellular isoform PrP protein that is also immunoreactive with the same antisera used for the Western blotting.

5

Ikegami et al. (1991) and Muramatsu et al. (1993) need to prepare the samples for Western blot analysis by various steps. They first enrich the samples by preparing tissue extracts containing fractions relatively enriched
10 for both PrP^{Sc} and PrP, after which the need to remove the PrP protein with a proteinase K treatment. This procedure entails at least 10 separate incubation and separation steps in which the absolute amount of the proteins to be detected in the sample is reduced at every step. Although
15 this protocol works very well for the diagnosis of the clinical phase of SE's, where an abundance of PrP^{Sc} is present in relation to the normal cellular isoform PrP, in the preclinical phase of TSE, the absolute amount of PrP^{Sc} is so small that it usually gets lost during the
20 preparation.

In BSE, the situation differs from that of scrapie: on the one hand, results from mice-transmission experiments using different tissues of BSE affected cattle, may indicate that distribution of the BSE agent in
25 tissues outside the CNS is not as extensive as in the case of scrapie in sheep, on the other hand it may be that the mice used in the bio-assays are far less sensitive for BSE than for scrapie. Experimental transmission of BSE to mice only succeeded when brain material was used (Fraser et
30 al., 1988; Fraser et al., 1990); mice inoculated with other materials, including spleen, semen, buffy coat, muscle, bone marrow and placenta remained healthy.

However, all above techniques other than bio-assays
35 have in common that diagnosis of SEs can only be established in the clinical phase of the disease, often at autopsy only. Considering the fact that bio-assays are

very slow, due to the very slow progress of the disease in the experimental animal that is used for the bio-assay as such, no methods are currently available that offer immediate diagnoses of SEs in a pre-clinical phase of the disease. Thus, although the average expert in diagnostic test development has currently a wealth of diagnostic techniques available to detect all kinds of proteins in biological samples, using monoclonal or polyclonal antisera in enzyme- or label-linked immunoassays, using techniques with or without enriching methods for the protein under study, no gold-standard is available to give guidance to the development of those diagnostic techniques that would be applicable in the case of pre-clinical diagnosis of prion disease. In other words, methods to establish sophisticated diagnostic tests are currently well known to the general expert in the field; the expert lacks, however, methods to establish the sensitivity and specificity of those sophisticated diagnostic tests due to the lack of a gold-standard.

20

We have now found a reliable and fast diagnostic method for pre-clinical diagnosis of prion diseases or SE's. The invention offers a method for pre-clinical diagnosis in sheep scrapie but also for other SEs like BSE and CJD. We used scrapie in sheep as a model to study SEs. Knowledge of the group of SEs, which includes the human forms such as CJD and Kuru, has been largely obtained from studies with scrapie. Scrapie is a progressive and fatal neurological disease of sheep and goats and is considered the "archetype" of the group of SEs and the probable cause for the BSE epidemic in the United Kingdom. The control and sanitary measures taken during the outbreak of BSE in the UK were also largely based on what was known about scrapie. Taking into account the above mentioned data of Hadlow on the presence of infectivity in various peripheral tissues, we concluded that among others lymphoid tissue would be a candidate for the development

35

of a preclinical test based on detection of PrP^{Sc}, but also other tissues, such as but not limited to retina, alveolar macrophages or monocytes, where PrP infectivity is found.

- 5 In our hand, immune histochemistry (IHC) using the immuno-peroxidase staining method, when used on histological sections of the brains for diagnosing clinical scrapie and BSE, proved a highly reliable and practical method for detecting PrP^{Sc} (Van Keulen et al, 10 1995) and less-cumbersome than Western blotting. Using the same IHC-technique and the same antisera, we examined a number of lymphoid tissues in a group of naturally affected, clinically-positive scrapie sheep (n=55) (Van Keulen et al, in press, see also the experimental part).
- 15 We demonstrated the presence of PrP^{Sc} in the spleen, the retropharyngeal lymph node, mesenteric lymph node and the palatine tonsils, in all but one of the animals (98%). Of all examined lymph nodes, tonsils were found having the highest PrP^{Sc} deposition rate that could be detected per 20 number of follicles: in all positive cases, more than 60% of the tonsil follicles stained positive and in 95% of these cases this was even more than 80%. To assess the applicability of this method in the pre-clinical phase of scrapie, we embarked upon a study involving sequential 25 biopsy taking of tonsils in sheep, tonsils were chosen while the experimental availability for sequential studies is guaranteed, however, using other tissues can as well be contemplated for pre-clinical diagnosis. We have detected the scrapie associated PrP^{Sc} in tonsils of 10 months old 30 sheep, which is at less than half-way the incubation period as the sheep under study are expected to develop scrapie when approximately 25 months old. In sheep that are expected to develop scrapie at a much later stage or stay healthy during their whole life span, we did not 35 detect this PrP^{Sc} protein.

With regard to scrapie, future control programmes could profit from these findings. Control programmes in several breeds could consist of a combination of breeding programmes that make use of the established linkage
5 between PrP genotype and increased scrapie-susceptibility or -resistance, and the above described method that detects the pathognomonic presence of PrP^{Sc} in tonsils of susceptible animals in the preclinical stage of the disease.

10 With regard to BSE, and SEs in general, changes and adjustments of the technique used can now be made to adjust to the specific circumstances and conditions of BSE, and SE, diagnosis. Those changes can be guided by specific knowledge about homologies and heterologies in
15 the amino acid sequences of prion proteins from different species (for a selection of known sequences see Figure 1). Also, guidance may found in selecting specific antisera by selecting for reactivity of selected continuous or discontinuous peptide sequences of those prion proteins.
20 First of all, the IHC-technique may be further refined for use in BSE and in peripheral lymph nodes in particular. This could require adaptations of the protocol in use for immuno-staining of brain sections. PrP^{Sc} detection in lymphoid tissues has been tried only using immuno-blotting
25 methods and in clinical cases (Mohri et al., 1992). These results were negative, indicating a detection problem with regard to sensitivity. No serious efforts have been made to detect PrP^{Sc} in preclinical stages of BSE. The technique of taking tonsillar biopsies in live cattle is
30 feasible and even easier than in sheep, as cattle can do with a light sedation (Xylazine (Rompun)). The possibility of an early diagnosis in case of BSE could alleviate the need for certain draconical measures proposed today with regard to the cattle population in the UK.

35 Far reaching implications of our invention lie in the field of human SEs. Also here the applicability of the IHC technique in the preclinical phase can now be established.

In literature, we did not find any reference to the examination of lymphoid tissues in this context. With tonsils being more readily accessible and with almost always access to a pathologic-anatomical laboratory, the
5 above described technique, applied in human SEs, could contribute to an early diagnosis of suspected cases of SEs. This allows the possibility of detecting individuals harbouring the disease at a moment early in the incubation period, at least considerably long before
10 clinical signs appear, which in turn would allow certain therapeutic measures to be applied for specific groups at risk (at least interventions that delay the progression of the disease, such as the use of amphotericin-B).

The present invention thus provides methods for the
15 detection of prion disease whereby aberrant proteins are detected in various tissues, such as but not limited to lymphoid or tonsillar tissue, which can be sampled from live animals, in particular from farm animals or humans or other mammals. The invention also provides methods that
20 distinguish between aberrant and normal protein, by i.e. removing the normal protein with methods that proteolyse, hydrolyse or denature the normal protein, or by immunologically detecting the aberrant protein.

Immunological detection entails any method currently known
25 by the expert in diagnostic test development, all methods employing immunological detection with enzym- or labellinked or nonlinked antibodies, even Western blotting techniques, may now be developed into sensitive and specific techniques, due to the fact that a gold-standard
30 for pre-clinical diagnosis of prion disease has now become available. These methods may also be developed into diagnostic tests or testkits comprising the necessary elements of any of above methods. The invention further provides use of any of above methods, tests or testkits in
35 the diagnosis of prion disease, in disease control programmes, in the selection of meat fit for consumption and in the selection of blood or blood products.

EXPERIMENTAL

Immunohistochemical detection of prion protein in
5 lymphoid tissues of sheep with clinical cases of natural
scrapie.

Materials and Methods

10 Sheep. Sixty seven sheep with nervous disorders
resembling those of a scrapie infection were purchased.
Fifty-five sheep were diagnosed with scrapie by
histopathological and immunohistochemical examination of
the brain. (Van Keulen et al., 1995) One animal suffered
15 from both a scrapie infection and a concurrent meningo-
encephalitis probably caused by *Listeria monocytogenes*.
Scrapie-positive sheep originated from 30 different
flocks. The group consisted of 54 females and one male
ranging in age from 2 to 5 years and comprised eight
20 different breeds and cross-breeds. Twelve sheep did not
show any histopathological signs of a scrapie infection
nor did they display any PrP^{Sc} immunostaining in the
brain. Five of these sheep were diagnosed with meningo-
encephalitis, one had intramyelinic edema of unknown
25 cause, and 6 sheep showed no histopathological abnormali-
ties. Scrapie-negative sheep were all females from 10
different flocks and two different breeds and crossbreeds,
ranging in age from 1 to 5 years.

Necropsy. Necropsy was performed within 36 hours
30 after natural death or immediately after killing the
animal by intravenous injection of sodium pentobarbital
and exsanguination. The brain was removed from each sheep
for scrapie diagnosis as described previously (van Keulen
et al, 1995). Samples were taken from several lymphoid
35 tissues including spleen, palatine tonsil, superficial
cervical lymph node (prescapular lymph node), subiliac
lymph node (prefemoral lymph node), medial retropharyngeal

lymph node, tracheobronchial lymph node, mesenteric lymph node, and ileum.

Histological and immunohistochemical procedures. Tissue samples were immediately immersed for 24 hours in periodate-lysine-paraformaldehyde fixative (PLP) containing 2% paraformaldehyde (Merck, Darmstadt, Germany). Samples were then trimmed to a maximum thickness of 2 mm and fixed for another 24 hours in freshly prepared PLP. After fixation, tissue samples were washed in water, routinely dehydrated and embedded in paraffin. Three sections of 5 μ m were cut, mounted on 3-aminoalkyltriethoxysilane-coated glass slides (Sigma, St. Louis MO, USA), dried for at least 48 hours at 60°C and deparaffinized. The first section was stained with hematoxylin-eosin (HE). Second and third sections were immunostained with anti-peptide serum directed against the ovine prion protein and pre-immune serum respectively according to the following procedure; after 30 minutes immersion in 98% formic acid (Merck), sections were washed and autoclaved immersed in water for another 30 minutes at 121°C in a pressure cooker. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide in methanol (Merck). Incubation at room temperature for 1 hour with anti-peptide antiserum or pre-immune serum, diluted 1:1500 in phosphate-buffered saline (pH 7.2) containing 1% bovine serum albumin (Sigma), was followed by incubation, first with biotin-conjugated goat-anti-rabbit IgG and then with streptavidin-peroxidase for 10 and 5 minutes respectively (Dakopatts, Glostrup, Denmark). As substrate we used aminoethylcarbazole (Zymed Laboratories Inc., San Francisco CA, USA) because its red color could easily be differentiated from the yellow-brownish ceroid/lipofuscin and hemosiderin pigment which was often present in the lymphoid tissues. Between the various steps, sections were thoroughly rinsed in phosphate-buffered saline containing 0.05% Tween-20 (Merck). Sections were counterstained with Mayer's hematoxylin for 30 seconds and mounted in

Glycergel (Dakopatts). With every immunohistochemical staining, a section of the medulla oblongata of a confirmed scrapie-affected sheep was simultaneously stained for PrP to check correct immunostaining

5 procedures.

Peptide synthesis and anti-peptide antisera. Five peptides with sequences derived from the ovine prion protein (PrP 94-105, 100-111, 126-143, 145-177, 223-234) were synthesized and used to raise anti-peptide antisera
10 in rabbits following previously published procedures (van Keulen et al, 1995). Antisera were confirmed to be specific for PrP (both undigested and after proteinase K treatment) on western blots of partially purified prion protein from scrapie-affected sheep brain according to
15 established procedures (Hilmert and Diringer, 1984). Pre-immune sera were collected before immunization and served as negative control sera.

The sera used have advantages which are based on a mixture of empirical, theoretical and analytical values
20 the combination of which makes them invaluable in the diagnostic application. The preparation of the sera has been described in a publication of van Keulen et al., 1995. The immunochemical properties of these sera are partly published. The specific sera used in this example
25 have been designed for scrapie diagnosis, however, guidance can be found in the below given indications for the development of sera that are applicable in diagnosis of the other SEs, provided one selects the sequences as corresponding to the species specific sequence of the
30 prion protein. When needed one may select other animals than rabbits to generate the specific sera.

- 1: the sera have been induced with synthetic peptides with sequences based on the sequence of PrP protein.
- 2: the sera have been induced in rabbits.
- 35 3: the peptides sequences have such differences with the rabbit PrP sequence that they induced not only antibodies which recognized these peptides but also the authentic PrP

protein.

- 4: the peptides used for immunization are kept short (12mers); this shortness is supposed to have a critical role in the high specificity for the scrapie forms of PrP and thus in the binding in the tissue sections even after harsh denaturing and degradative treatments.
- 5: the sequences used for immunization and yielding the specific scrapie PrP staining were selected from the protease K resistant domain of the PrP^{Sc}.
- 10 6: the sera of use in the diagnostic IHC are also well reactive in other immunochemical tests such as: Western blotting of both PrP^C and PrP^{Sc}, ELISA with PrP protein, PEPSCAN with 12mer peptides with overlapping sequences of sheep PrP.
- 15 7: the peptides selected have properties (hydrophilicity, flexibility, surface occurrence) which are - when used for immunization - advantageous for eliciting antibodies with binding to the antigen on which the sequences have been based.
- 20 8: the antisera elicited show the right specificity when analyzed in PEPSCAN with 12mer peptides. The addition of a foreign dimeric glycine at either the N-terminus or the C-terminus of these peptides does not decrease the specificity of the peptides but more probably does make the immunization more effective, supposedly because it makes the peptides stand out farther away from the carrier protein and makes them more flexible on the carrier protein properties which are important determinants in antigenicity.
- 25 9: the sequences selected for peptide synthesis and immunization represent domains which have a low tendency to form secondary structure (α -helix or β -sheet) and are not part of the four regions described in the literature as being able to form β -sheet as synthetic peptides.
- 30

35

Results

Immunohistochemical testing of antipeptide antisera.

An identical and distinct immunolabelling pattern was detected with all anti-peptide antisera in the lymphoid
5 tissues of scrapie-affected sheep. Because the five antisera were directed against different epitopes of the PrP protein, cross-reactivity of the anti-peptide antisera with another protein can be excluded. We therefore classified the immunolabelled protein as PrP. We further
10 defined this PrP as scrapie-associated PrP (PrP^{Sc}), because no PrP immunoreactivity was seen in any of the lymphoid tissues of scrapie-negative sheep. Replacing the anti-peptide antisera with pre-immune sera did not result in any immunolabelling.

15

Localization of PrP^{Sc} in the lymphoid tissues.

PrP^{Sc} was located within the primary and secondary lymphoid follicles of the spleen, palatine tonsil, lymph nodes, and solitary follicles or Peyer's patches of the
20 ileum (Fig. 1 A-C). The PrP^{Sc} immunolabelling pattern consisted of a reticular network in the center of the lymphoid follicle which varied in staining intensity. Apart from this network, fine to coarse granules of PrP^{Sc} were seen in the cytoplasm of non-lymphoid cells within
25 the follicle. Several of these cells were identified as macrophages because of the simultaneous presence of ceroid/lipofuscin pigment in their cytoplasm (Fig. 1D). No immunolabelling of the B lymphocytes in the lymphoid follicle was seen.

30 Occasionally, additional immunolabelling was found in specific cells and regions of the lymphoid tissues. In the spleen, individual cells in the periarterial lymphatic sheath (PALS) and the marginal zone surrounding the splenic corpuscles contained granules of PrP^{Sc} sometimes
35 combined with ceroid/lipofuscin pigment within the cytoplasm. No PrP^{Sc} was seen in the red pulp of the spleen. In the palatine tonsil and ileum, branches or

granules of PrpSc were found interspersed between the lymphocytes of the dome area between the follicles and the crypt epithelium. In the lymph nodes, granules of PrpSc were seen between the lymphocytes of the paracortex.

5

Distribution of PrpSc in lymphoid tissues.

PrpSc was detected in 54 (98%) of the 55 scrapie-affected sheep in the spleen, tonsil, retropharyngeal lymph node and mesenteric lymph node. In the tracheobronchial, prefemoral and prescapular lymph node, PrpSc was seen in a slightly lower percentage of the sheep (table 1). PrpSc was found in solitary lymphoid follicles or Peyer's patches of the ileum in 24 (89%) of the 27 sheep in which lymphoid tissue was present in the sections of the ileum. In only 1 of the 55 scrapie-affected sheep, PrpSc could not be detected in any of the lymphoid tissues.

The percentage of lymphoid follicles that contained PrpSc was estimated for the sections of the spleen, tonsil and lymph nodes. In the palatine tonsil of 98% of the scrapie-affected sheep, over 60% of the lymphoid follicles contained PrpSc. In the tonsils of 93% of the sheep with scrapie, the percentage of PrpSc-positive lymphoid follicles even exceeded 80%. In the spleen or lymph nodes, PrpSc accumulation in more than 60% of the lymphoid follicles was only present in less than 30% of the sheep.

Immunohistochemical detection of prion protein in lymphoid tissues of sheep with pre-clinical cases of natural scrapie.

Material and methods

Sheep.

We selected a group of 10 purposely bred lambs, six of them homozygous for the PrP allele with valine (V) at position 136 and glutamine (Q) at position 171. In several

breeds, this PrP^{VQ} allele is significantly associated with an increased susceptibility for scrapie (Belt et al, 1995). The remaining four lambs were heterozygous and possessed one PrP^{VQ} allele and one PrP^{AR} allele (alanine at position 136 and arginine at position 171). The PrP^{AR} allele is significantly associated with increased resistance of sheep for scrapie. In a flock with natural scrapie we observed that sheep with the genotype PrP^{VQ}/VQ died from scrapie at approximately 25 months of age and that the majority of the sheep with the genotype PrP^{VQ}/AR were still healthy at 70 months of age. Since we expected that the PrP^{VQ}/VQ sheep would almost certainly develop clinical signs of scrapie within approximately 25 months after birth and that the PrP^{VQ}/AR sheep would stay healthy, we regarded these two groups of sheep as a suitable model to study changes at known stages of the incubation period. All 10 sheep were born and raised on the same farm, in an environment where scrapie has been occurring for several years. They were kept here until six months old, when they were transferred to our Institute, to a paddock where various scrapie positive animals had spent their last days.

Sampling and testing of tonsils of the live animal

Tonsil biopsies were collected under general anaesthesia, which was achieved by intravenous application of a combination of Ketalar (Ketamine-HCl) 4 mg/kg, Xylazine (Rompun) 0.05 mg/kg and Atropine 0.1 mg/kg. We used a mouth gag, a laryngoscope, and a biopsy forceps with a head of approximately 4 mm in diameter. Tonsils in sheep are not as readily accessible as in some other species, such as man, where they often protrude into the pharyngeal lumen. In sheep, they are hidden, surrounding a small cavity. It proved, however, sufficient to take a biopsy of the edge of the entrance to this cavity, the fossa tonsillaris, thereby collecting in general sufficient material (follicles!) to allow examination. Some experience in the technique was obtained by collecting, just before the animals were euthanised, tonsillar biopsies from 11 sheep, among them clinically affected scrapie sheep. Histological procedures included immunostaining with specific (anti-PrP^{Sc}) anti-peptide-sera, as described above and in Van Keulen et al, 1995. From the 11 sheep, eight proved to be scrapie positive while three turned out negative, as was confirmed histologically and by IHC of brain tissue during post mortem examination. The tonsillar biopsies of all eight positive animals showed a positive immuno-staining in the IHC, whereas no immuno-staining could be detected in the three negative cases.

In the actual experiment, we planned to take tonsillar biopsies sequentially, at regular intervals and starting at an age of six months. For logistic reasons this was delayed. We collected biopsies from both groups for the first time at approximately 10 months after birth, when none of the sheep showed clinical signs of scrapie. The youngest sheep were nine-and-half months, the oldest sheep was 10 months and one week.

Results.

After IHC-staining we found clear, already extensive, PrP^{Sc} staining in the tonsillar biopsies of all six
5 susceptible PrP^{VQ/VQ} sheep, whereas no immuno-staining was detectable in the tonsillar biopsies of any of the resistant PrP^{VQ/AR} sheep. We have thus detected the scrapie associated PrP^{Sc} in tonsils of 10 months old
10 sheep, which is at less than half-way the incubation period as they are expected to develop scrapie when approximately 25 months old. In sheep that are expected to develop scrapie at a much later stage or stay healthy during their whole life span, we did not detect this PrP^{Sc} protein. We conclude that IHC-staining and related methods
15 provide the possibility for pre-clinical diagnosis in sheep scrapie as well as for other SEs like BSE and CJD.

REFERENCES

- Belt, P.B.G.M., I. H. Muileman, B. E. C. Schreuder, J. Bos-de Ruijter, A. L. J. Gielkens, and M. A. Smits. 1995. Identification of five allelic variants of the sheep PrP gene and their association with natural scrapie. *J. Gen. Virol.* 76:509-517.
- Fraser, H. and A. G. Dickinson. 1978. Studies of the lymphoreticular system in the pathogenesis of scrapie: the role of spleen and thymus. *J. Comp. Pathol.* 88:563-573.
- Hadlow, W.J., R. C. Kennedy, and R. E. Race. 1982. Natural infection of Suffolk sheep with scrapie virus. *J. Infect. Dis.* 146:657-664.
- Hilmert, H. and H. Diringer. 1984. A rapid and efficient method to enrich SAF protein from scrapie brains of hamsters. *Biosci. Rep.* 4:165-170.
- Ikegami, Y., M. Ito, H. Isomura, E. Momotani, K. Sasaki, Y. Muramatsu, N. Ishiguro, and M. Shinagawa. 1991. Pre-clinical and clinical diagnosis of scrapie by detection of PrP protein in tissues of sheep. *Vet. Rec.* 128:271-275.
- Mohri, S., C. F. Farquhar, R. A. Somerville, M. Jeffrey, J. Foster, and J. Hope. 1992. Immunodetection of a disease specific PrP fraction in scrapie-affected sheep and BSE-affected cattle. *Vet. Rec.* 131:537-539.
- Muramoto, T., T. Kitamoto, J. Tateishi, and I. Goto. 1993. Accumulation of abnormal prion protein in mice infected with Creutzfeldt-Jakob disease via intraperitoneal route: a sequential study. *Am. J. Pathol.* 143:1470-1479.

- van Keulen, L.J.M., B. E. C. Schreuder, R. H. Meloen, G. Mooij-Harkes, M. Poelen-van den Berg, M. E. W. Vromans, and J. Langeveld. 1995. Immunohistochemical detection and localization of prion protein in brain tissue of sheep with natural scrapie. *Vet. Pathol.* 32:299-308.
- Brown, P. Current opinion in Hematology 2, 472-477 (1995)
- Brugère H, Banissi C, Brugère-Picoux J, Chatelain J and Buvet R. Recherche d'un témoin biochimique urinaire de l'infection du mouton par la tremblante. *Bull acad vet de France* 1991; 64: 139-45.
- Diringer H, Gelderblom H, Hilmert H, Özel M, Edelblut C, and Kimberlin RH. Scrapie infectivity, fibrils and low molecular weight protein. *Nature* 1983; 306: 476-8.
- Doi S, Ito M, Shinagawa M, Sato G, Isomura H, and Goto H. Western blot detection of scrapie-associated fibril protein in tissues outside the central nervous system from preclinical scrapie-infected mice. *J gen Virol* 1988; 69:955-60.
- Fraser H, Bruce ME, and McConnell I. Murine scrapie strains, BSE models and genetics. In: *Sub-Acute spongiform Encephalopathies. Procs of a Seminar in CEC Agricultural Research Programme, Brussels, 12-14 November 1990* (Bradley R, Savey M, and Marchant BA, eds.). Kluwer Academic Publishers, Dordrecht, The Netherlands 1991; 131-6.
- Hadlow WJ, Kennedy RC and Race RE. Natural infection of Suffolk sheep with scrapie virus. *J Inf Dis* 1982; 146: 657-64
- Hadlow WJ, Kennedy RC, Race RE and Eklund CM. Virologic and histologic findings in dairy goats affected with natural scrapie. *Vet Pathol* 1980; 17: 187-99.

Fraser H, McConnell I, Wells GAH, and Dawson M.
Transmission of bovine spongiform encephalopathy to mice.
Vet Rec 1988; 123: 472.

5

Meiner Z, Halimi M, Polakiewicz RD, Prusiner SB and
Gabizon R. Presence of prion protein in peripheral tissues
of Libyan Jews with Creutzfeld-Jacob disease. Neurology
1992; 42, 1355-1360

10

Schreuder B Animal spongiform encephalopathies - an
update. Part 1. Scrapie and lesser known animal spongiform
encephalopathies. Vet Quart. 1994; 16, 174-181

15 Schreuder B Animal spongiform encephalopathies - an
update. Part 2. Bovine spongiform encephalopathy. Vet
Quart. 1994; 16, 182-192

Muramatsu Y, Onodera A, Horiuchi M, Ishigano N and
20 Shinagawa M. Detection of PrP^{Sc} in sheep at the
preclinical stage of scrapie and its significance for
diagnosis of insidious infection. Arch.Virol 134;427-432
(1993)

CLAIMS

- 1 Method for the detection of prion disease whereby
aberrant proteins are detected in tissues which can be
sampled from live animals.
- 2 Method according to claim 1 whereby the animals are
5 mammalian.
- 3 Method according to claim 1 or 2 whereby the tissue
is lymphoid.
- 4 Method according to claim 3 whereby the tissue is
tonsillar.
- 10 5 Method according to claim 1, 2, 3 or 4 which
distinguishes between aberrant and normal protein.
- 6 Method according to claim 5 whereby normal protein is
removed.
- 7 Method according to claim 5 whereby aberrant protein
15 is immunologically detected.
- 8 Method according to anyone of claims 1-7 whereby
prion disease is detected at a pre-clinical phase.
- 9 Diagnostic test or testkit comprising the necessary
elements for carrying out a method according to anyone of
20 claims 1-8.
- 10 10 Diagnostic test or testkit according to claim 9
further comprising enzyme- or label-linked or non-linked
antibodies.
- 11 11 Use of the method of anyone of claims 1-8 or
25 diagnostic test or testkit of claims 9 or 10 in the
diagnosis of prion disease, or in disease control
programmes, or in the detection of aberrant protein in
products of animal origin.

Figure 1 Multiple sequence allingment of prion proteins of various origin.

Perfectly conserved: '+'	Disulfide-bond: '\$'	
Well conserved: '.'	N-Glycosylation: '#'	
-----sign-----		
SHPRP	MVKSHIGSWILVLFVAMWSDVGLCKKRPKPGGGWNTGGSRYPGQGSPPGN	50
BTPRP	MVKSHIGSWILVLFVAMWSDVGLCKKRPKPGGGWNTGGSRYPGQGSPPGN	50
MINKPRP	MVKSHIGSWLLVLFVATWSDIGFCKKRPKPGGGWNTGGSRYPGQGSPPGN	50
GORPRP	M--ANLGYWMLVLFVATWSDLGLCKKRPKPGG-WNTGGSRYPGQGSPPGN	47
HSPRP	M--ANLGCWMLVLFVATWSDLGLCKKRPKPGG-WNTGGSRYPGQGSPPGN	47
MAPRP	M--ANLSYWLLALFVAMWTDVGLCKKRPKPGG-WNTGGSRYPGQGSPPGN	47
MMPRP	M--ANLGYWLLALFVTMTWTDVGLCKKRPKPGG-WNTGGSRYPGQGSPPGN	47
RRPRP	-----GGWNTGGSRYPGQGSPPGN	19+
+ *****		
SHPRP	RYPPQGGGGWGQPHGGGGWGQPHGGGGWGQPHGGGGWGQPHGGG-----G	92
BTPRP	RYPPQGGGGWGQPHGGGGWGQPHGGGGWGQPHGGGGWGQPHGGGGWGQPHGGGG	100
MINKPRP	RYPPQGGGGWGQPHGGGGWGQPHGGGGWGQPHGGGGWGQPHGGG-----G	92
GORPRP	RYPPQGGGGWGQPHGGGGWGQPHGGGGWGQPHGGGGWGQPHGG-----G	88
HSPRP	RYPPQGGGGWGQPHGGGGWGQPHGGGGWGQPHGGGGWGQPHGG-----G	88
MAPRP	RYPPQGGGTWQPHGGGGWGQPHGGGGWGQPHGGGGWGQPHGG-----G	88
MMPRP	RYPPQGG-TWQPHGGGGWGQPHGGGGWGQPHGGGGWGQPHGG-----G	87
RRPRP	RYPPQSGGTWQPHGGGGWGQPHGGGGWGQPHGGGGWGQPHGG-----G	60+
***** . . ***** . ***** . *****		
SHPRP	WGQGG-SHSQWNKPSKPKTNMKHVAGAAAAGAVVGGGLGGYMLGSAMSRPL	141
BTPRP	WGQGG-THGQWNKPSKPKTNMKHVAGAAAAGAVVGGGLGGYMLGSAMSRPL	149
MINKPRP	WGQGGGSHGQWGKPSKPKTNMKHVAGAAAAGAVVGGGLGGYMLGSAMSRPL	142
GORPRP	WGQGGGTHSQWNKPSKPKTNMKHMAGAAAAGAVVGGGLGGYMLGSAMSRPI	138
HSPRP	WGQGGGTHSQWNKPSKPKTNMKHMAGAAAAGAVVGGGLGGYMLGSAMSRPI	138
MAPRP	WGQGGGTHNQWNKPSKPKTNMKHMAGAAAAGAVVGGGLGGYMLGSAMSRPM	138
MMPRP	WGQGGGTHNQWNKPSKPKTNLKHVAGAAAAGAVVGGGLGGYMLGSAMSRPM	137
RRPRP	WSQGGGTHNQWNKPSKPKTNLKHVAGAAAAGAVVGGGLGGYMLGSAMSRPM	110+
* . * . * . * . * . * . * . * . * . * . * . * . * . * . * . *		
\$ #		
SHPRP	IHFGNDYEDRYRENMYRYPNQVYYRFPVDQYSNQNNFVHDCVNITVKQHT	191
BTPRP	IHFGSDYEDRYRENMYRYPNQVYYRPVDQYSNQNNFVHDCVNITVKEHT	199
MINKPRP	IHFGNDYEDRYRENMYRYPNQVYYKRPVDQYSNQNNFVHDCVNITVKQHT	192
GORPRP	IHFGSDYEDRYRENMYRYPNQVYYRPMQDQYSNQNNFVHDCVNITIKQHT	188
HSPRP	IHFGSDYEDRYRENMYRYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHT	188
MAPRP	MHFGNDWEDRYRENMYRYPNQVYYRPVDQYNNQNNFVHDCVNITIKQHT	188
MMPRP	IHFGNDWEDRYRENMYRYPNQVYYRPVDQYSNQNNFVHDCVNITIKQHT	187
RRPRP	LHFGNDWEDRYRENMYRYPNQVYYRPVDQYSNQNNFVHDCVNITIKQHT	160+
. * . * . * . * . * . * . * . * . * . * . * . * . * . * . *		
# \$		
SHPRP	VTTTTKGENFTETDIKIMERVVEQMCITQYQRESQAYYQ--RGASVILFS	239
BTPRP	VTTTTKGENFTETDIKIMERVVEQMCITQYQRESQAYYQ--RGASVILFS	247
MINKPRP	VTTTTKGENFTETDMKIMERVVEQMCITQYQRESEAYYQ--RGASAILFS	240
GORPRP	VTTTTKGENFTETDVKIMERVVEQMCITQYERESQAYYQ--RGSSMVILFS	236
HSPRP	VTTTTKGENFTETDVKIMERVVEQMCITQYERESQAYYQ--RGSSMVILFS	236
MAPRP	VTTTTKGENFTETDIKIMERVVEQMCITQYQKESQAYYDGRSSA-VLFS	237
MMPRP	VTTTTKGENFTETDVKIMERVVEQMCVTQYQKESQAYYDGRSSSTVLFS	237
RRPRP	VTTTTKGENFTETDVKIMERVVEQMCVTQYQKESQAYYDGRSSA-VLFS	209+
***** . * . ***** . * . * . * . * . * . * . * . * . *		

Figure 1, continued

---GPI---

SHPRP	SPPVILLISFLIFLIVG	256
BTPRP	SPPVILLISFLIFLIVG	264
MINKPRP	PPPVILLISLLILLIVG	257
GORPRP	SPPVILLISFLIFLIVG	253
HSPRP	SPPVILLISFLIFLIVG	253
MAPRP	<u>SPPVILLISFLIFLMVG</u>	254
MMPRP	SPPVILLISFLIFLIVG	254
RRPRP	SPPVILLISFLIFLIVG	226+
	.*****+.***.***	

Dictionary of the sequences which have been aligned

```

=====
[ 1] SHPRP
DE  PROTEINSEQ OF SHPRP NT 72-839
    Size: 256 residues.
[ 2] MINKPRP
DE  MINK TRANSL BY ALX 41-814
    Size: 257 residues.
[ 3] GORPRP
DE  GORPRP TRANSL FROM 1-762 BY ALX
OS  GORILLA
    Size: 253 residues.
[ 4] MAPRP
DE  MAPRP TRANSL FROM 11-733 BY ALX   AA MANLSYWLLALFVA ADDED
OS  SYRIAN GOLDEN HAMSTER
    Size: 254 residues.
[ 5] BTPRP
DE  BOVINE PRP GENE FOR A PRION-PROTEIN.
OS  BOS TAURUS (CATTLE)
    Size: 264 residues.
[ 6] HSPRP
DE  HOMO SAPIENS PRP GENE TRANSL FROM 50-811 BY ALX
OS  HOMO SAPIENS
    Size: 253 residues.
[ 7] MMPRP
DE  MMPRP TRANSL FROM 107-871 BY ALX
OS  MURINE PRP
    Size: 254 residues.
[ 8] RRPRP
DE  RAT PRION-RELATED PROTEIN (PRP) MRNA TRANSL <1? TO 678 FRAME 1
    (ALX)
OS  RATTUS RATTUS (RAT)
    Size: 226 residues.

```

INTERNATIONAL SEARCH REPORT

Intern. Application No
PCT/NL 97/00166

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 G01N33/68 G01N33/569

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ARCHIVES OF VIROLOGY, vol. 134, no. 3-4, 1993, WIEN, pages 427-432, XP000196297 MURAMATSU ET AL.: "Detection of PrPSC in sheep at the preclinical stage of scrapie and its significance for diagnosis of insidious infection" cited in the application see the whole document</p> <p style="text-align: center;">--- -/--</p>	1-3,5-11

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search 2 June 1997	Date of mailing of the international search report 24-06-1997
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Ceder, O

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/NL 97/00166

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	THE VETERINARY RECORD, vol. 128, no. 12, 23 March 1991, LONDON, pages 271-275, XP000196191 IKEGAMI Y ET AL: "PRE-CLINICAL AND CLINICAL DIAGNOSIS OF SCRAPIE BY DETECTION OF PRP PROTEIN IN TISSUES OF SHEEP" cited in the application see abstract	1-3,8-11
Y	see page 273, right-hand column, line 34 - line 37	5-7
Y	WO 93 23432 A (UNIV NEW YORK ;INST NAZIONALE NEUROLOGICO C B (IT)) 25 November 1993 see page 11, line 37 - page 12, line 6	5-7
A	VETERINARY PATHOLOGY, vol. 17, 1980, WASHINGTON DC, pages 187-199, XP000196298 HADLOW ET AL.: "Virologic and neurohistologic findings in dairy goats affected with natural scrapie" cited in the application see page 189, line 3 - line 4; table 1	4
A	US 4 806 627 A (WISNIEWSKI HENRYK M ET AL) 21 February 1989 see column 3, line 28 - line 45	1-3
A	JOURNAL OF GENERAL VIROLOGY, vol. 69, no. 3, 1 March 1988, READING, pages 955-960, XP000196197 DOI S ET AL: "WESTERN BLOT DETECTION OF SCRAPIE-ASSOCIATED FIBRIL PROTEIN IN TISSUES OUTSIDE THE CENTRAL NERVOUS SYSTEM FROM PRECLINICAL SCRAPIE-INFECTED MICE" cited in the application see abstract	1-3,8

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NL 97/00166

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9323432 A	25-11-93	AU 4376093 A	13-12-93
US 4806627 A	21-02-89	NONE	